You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Formoterol as reliever medication in asthma: a post-hoc analysis of the subgroup of the RELIEF study in East Asia
|
|---|---|
| Published in |
BMC Pulmonary Medicine, January 2016
|
| DOI | 10.1186/s12890-015-0166-0 |
| Pubmed ID | |
| Authors |
Qi Jian Cheng, Shao-Guang Huang, Yu Zhi Chen, Jiang-Tao Lin, Xin Zhou, Bao-Yuan Chen, Yu-Lin Feng, Xia Ling, Malcolm R. Sears, on behalf of the RELIEF Asia Study investigators |
| Abstract |
As-needed formoterol can effectively relieve asthma symptoms. Since budesonide/formoterol is available as maintenance and reliever therapy in Asia, formoterol is now being used as-needed, but always with concomitant inhaled corticosteroids. The objective of this analysis was to assess the safety and efficacy of formoterol therapy in patients in East Asia (China, Indonesia, Korea, the Philippines and Singapore) with asthma. Post-hoc analyses of data from the East Asian population of the RELIEF (REal LIfe EFfectiveness of Oxis® Turbuhaler® as-needed in asthmatic patients; study identification code: SD-037-0699) study were performed. This sub-group comprised 2834 randomised patients (formoterol n = 1418; salbutamol n = 1416) with mean age 35 years; 50.7 % were male. 2678 patients completed the study. There was no significant difference in the total number of adverse events (AEs) reported in the formoterol and salbutamol groups (21.3 % vs 20.9 % of patients; p = 0.813), nor in the total number of serious AEs and/or discontinuations due to AEs (4.6 % vs 5.5 %, respectively; p = 0.323). Compared with salbutamol, formoterol was associated with a significantly longer time to first exacerbation (hazard ratio 0.86; p = 0.023) and a 14 % reduction in the risk of any exacerbation (p < 0.05). Relative to salbutamol, mean adjusted reliever medication use throughout the study was significantly lower in the formoterol group (p = 0.017) and the risk of increased asthma medication use was 20 % lower with formoterol (p = 0.005). Among patients with asthma in East Asia, as-needed formoterol and salbutamol had similar safety profiles but, compared with salbutamol, formoterol reduced the risk of exacerbations, increased the time to first exacerbation and reduced the need for reliever medication. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 60 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 60 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 8 | 13% |
| Researcher | 7 | 12% |
| Other | 7 | 12% |
| Student > Master | 6 | 10% |
| Student > Postgraduate | 4 | 7% |
| Other | 10 | 17% |
| Unknown | 18 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 35% |
| Nursing and Health Professions | 8 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 7% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Business, Management and Accounting | 1 | 2% |
| Other | 4 | 7% |
| Unknown | 19 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 January 2016.
All research outputs
#18,436,183
of 22,840,638 outputs
Outputs from BMC Pulmonary Medicine
#1,382
of 1,921 outputs
Outputs of similar age
#285,487
of 395,131 outputs
Outputs of similar age from BMC Pulmonary Medicine
#29
of 41 outputs
Altmetric has tracked 22,840,638 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,921 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one is in the 17th percentile – i.e., 17% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 395,131 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 41 others from the same source and published within six weeks on either side of this one. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.